785 articles
A pilot trial finds duodenal mucosal resurfacing cuts post-tirzepatide weight rebound nearly in half, offering a potential off-ramp from lifelong GLP-1 therapy.
Intellia's in-vivo gene-editing therapy lonvo-z slashed hereditary angioedema attacks 87% vs placebo in a Phase 3 trial of 80 patients.
New research shows senescent cells play a vital healing role in youth — and losing this response may explain why wounds heal slower with age.
Calluna Pharma's CAL101 monoclonal antibody enters Phase 2 testing for IPF, a fatal lung disease with only 3–5 year median survival.
4Moving Biotech's 4P004 targets joint inflammation and tissue breakdown — not just pain — in a disease affecting 374 million people.
Strength expert JJ Virgin argues muscle mass — not weight — is the true foundation of longevity, backed by grip strength data and metabolic science.
A landmark grant renews the Long Life Family Study, while centenarian blood protein data and new geroscience calls reshape longevity research.
McGill researchers pinpointed two brain cell types altered in depression, opening doors to targeted biological treatments.
A 50,000-patient study finds same-day gabapentin after TBI cuts cognitive impairment risk by 22% and mortality by 46% in severe cases.
New MUSC research finds EPA in fish oil could weaken brain vessel repair and worsen recovery after repeated mild traumatic brain injuries.
A gut microbe converts a common pollutant into an inflammation trigger linked to depression, revealing a new molecular pathway.
A polypill combining three BP drugs slashed recurrent stroke risk from 7.4% to 4.6% in hemorrhagic stroke survivors, per a New England Journal study.
